Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
YieldMax MRNA Option Income Strategy ETF(MRNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MRNY
10/09/2026: MRNY (1-star) has a low Upturn Star Rating. Not recommended to BUY.
MRNY provides investors with high monthly income by selling synthetic covered calls on Moderna, Inc. (MRNA) stock, effectively monetizing volatility. Its primary strengths are its simplicity and income-generating potential, which are attractive to retail investors seeking non-traditional yield. However, investors face significant risks, including uncapped downside exposure to MRNA and capped upside participation, which can lead to NAV erosion. The fund is best suited for income-focused investors who understand the risks of single-stock derivative strategies and are willing to monitor the underlying company's performance closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The capped upside potential limits the capital appreciation that growth investors typically seek. |
| Momentum investor | Weak fit | The option-based structure constrains the ability to fully capture strong upward momentum in MRNA shares. |
| Value investor | Weak fit | The fund strategy focuses on volatility harvesting rather than fundamental valuation or long-term growth prospects. |
| Dividend/Income investor | Strong fit | This fund is specifically designed for investors prioritizing high monthly income distributions over capital growth. |
| Low-risk investor | Weak fit | High volatility inherent in the underlying MRNA stock makes this a high-risk product. |
Investor Profile
Ideal Investor Profile
Income-focused investors who are bullish or neutral on Moderna and seek high monthly cash flow, while accepting the risk of NAV erosion and capped upside.
Suitability
Not suitable for long-term buy-and-hold investors looking for capital growth; better suited for yield-seeking tactical traders.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | The high volatility of the underlying MRNA stock significantly impacts the fund's net asset value. |
| Market risk | High | Investors are exposed to the full downside of MRNA while upside potential is capped by the covered call strategy. |
| Concentration | High | The fund's performance is tied entirely to a single security, eliminating the benefits of sector diversification. |
| Tracking/expense | Medium | The high expense ratio of 0.99% can erode long-term returns in a strategy already limited by option mechanics. |
| Liquidity | Medium | Options market liquidity on MRNA can affect the fund's execution costs during periods of extreme market stress. |
| Business/sector quality | Medium / high | The biotech industry is subject to rapid changes in drug development success and regulatory outcomes. |
Risk Analysis
Volatility
MRNY exhibits extremely high historical volatility due to its reliance on a single, volatile biotech stock and synthetic option mechanics.
Market Risk
The primary risk is the concentrated exposure to MRNA, meaning the fund is susceptible to company-specific news, clinical trial outcomes, and sector-wide sentiment.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Derivatives | Synthetic Moderna (MRNA) Long Position | 95 | This position provides synthetic exposure to MRNA price movements through a combination of long calls and short puts. |
| Cash/collateral | Cash and Cash Equivalents | 5 | Cash serves as collateral to support the derivative positions and manage liquidity requirements. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type ETF | Historic Profit 52.08% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/09/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.